BR112022014574A2 - Proteína heterodimérica, anticorpo ativável, um ou mais ácidos nucleicos, vetor, célula hospedeira, composição farmacêutica e métodos para preparar uma proteína heterodimérica ou um anticorpo ativável e para tratar uma doença - Google Patents

Proteína heterodimérica, anticorpo ativável, um ou mais ácidos nucleicos, vetor, célula hospedeira, composição farmacêutica e métodos para preparar uma proteína heterodimérica ou um anticorpo ativável e para tratar uma doença

Info

Publication number
BR112022014574A2
BR112022014574A2 BR112022014574A BR112022014574A BR112022014574A2 BR 112022014574 A2 BR112022014574 A2 BR 112022014574A2 BR 112022014574 A BR112022014574 A BR 112022014574A BR 112022014574 A BR112022014574 A BR 112022014574A BR 112022014574 A2 BR112022014574 A2 BR 112022014574A2
Authority
BR
Brazil
Prior art keywords
heterodimeric protein
activable antibody
methods
vector
disease
Prior art date
Application number
BR112022014574A
Other languages
English (en)
Inventor
Peizhi Luo Peter
Du Fangyong
Liu Guizhong
Dai Zhengxi
Shi Jianfeng
Lin Zhixiong
Li Yan
Original Assignee
Adagene Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adagene Ag filed Critical Adagene Ag
Publication of BR112022014574A2 publication Critical patent/BR112022014574A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROTEÍNA HETERODIMÉRICA, ANTICORPO ATIVÁVEL, UM OU MAIS ÁCIDOS NUCLEICOS, VETOR, CÉLULA HOSPEDEIRA, COMPOSIÇÃO FARMACÊUTICA E MÉTODOS PARA PREPARAR UMA PROTEÍNA HETERODIMÉRICA OU UM ANTICORPO ATIVÁVEL E PARA TRATAR UMA DOENÇA. O presente pedido fornece proteínas heterodiméricas que compreendem polipeptídeos tendo domínios CH3 com resíduos manipulados que formam ligações dissulfeto e/ou pontes de sal. Também são fornecidos anticorpos ativáveis que visam CD3 e/ou HER2. São fornecidas ainda composições, métodos de fabricação e métodos de tratamento que usam as proteínas heterodiméricas e os anticorpos ativáveis.
BR112022014574A 2020-01-23 2021-01-22 Proteína heterodimérica, anticorpo ativável, um ou mais ácidos nucleicos, vetor, célula hospedeira, composição farmacêutica e métodos para preparar uma proteína heterodimérica ou um anticorpo ativável e para tratar uma doença BR112022014574A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020073960 2020-01-23
PCT/CN2021/073347 WO2021148006A1 (en) 2020-01-23 2021-01-22 Heterodimeric proteins with fc mutations

Publications (1)

Publication Number Publication Date
BR112022014574A2 true BR112022014574A2 (pt) 2022-09-27

Family

ID=76992067

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014574A BR112022014574A2 (pt) 2020-01-23 2021-01-22 Proteína heterodimérica, anticorpo ativável, um ou mais ácidos nucleicos, vetor, célula hospedeira, composição farmacêutica e métodos para preparar uma proteína heterodimérica ou um anticorpo ativável e para tratar uma doença

Country Status (12)

Country Link
US (1) US20230124669A1 (pt)
EP (1) EP4093778A4 (pt)
JP (1) JP2023511376A (pt)
KR (1) KR20220145833A (pt)
CN (1) CN115279796A (pt)
AU (1) AU2021210482A1 (pt)
BR (1) BR112022014574A2 (pt)
CA (1) CA3165045A1 (pt)
IL (1) IL294878A (pt)
MX (1) MX2022009101A (pt)
TW (1) TW202140570A (pt)
WO (1) WO2021148006A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183888A1 (en) * 2022-03-23 2023-09-28 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2023193239A1 (en) 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553500A (en) * 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
CN106995495A (zh) * 2009-01-12 2017-08-01 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN107253992B (zh) * 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
AU2012328322A1 (en) * 2011-10-27 2014-06-12 Genmab A/S Production of heterodimeric proteins
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2014232501C1 (en) * 2013-03-15 2021-04-22 Xencor, Inc. Heterodimeric proteins
AU2014343636A1 (en) * 2013-11-04 2016-06-02 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
WO2016086186A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
JP6721590B2 (ja) * 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
CN106883297B (zh) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
SG11201900373WA (en) * 2016-07-19 2019-02-27 Ibentrus Inc Bispecific proteins and methods for preparing same
WO2019014912A1 (zh) * 2017-07-21 2019-01-24 赵磊 一种异二聚体蛋白及其制备方法

Also Published As

Publication number Publication date
TW202140570A (zh) 2021-11-01
MX2022009101A (es) 2022-10-07
EP4093778A1 (en) 2022-11-30
US20230124669A1 (en) 2023-04-20
AU2021210482A1 (en) 2022-08-25
JP2023511376A (ja) 2023-03-17
KR20220145833A (ko) 2022-10-31
EP4093778A4 (en) 2024-07-10
CN115279796A (zh) 2022-11-01
CA3165045A1 (en) 2021-07-29
IL294878A (en) 2022-09-01
WO2021148006A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
BR112022000371A2 (pt) Anticorpos claudin18 e métodos de tratamento contra câncer
BR112022014574A2 (pt) Proteína heterodimérica, anticorpo ativável, um ou mais ácidos nucleicos, vetor, célula hospedeira, composição farmacêutica e métodos para preparar uma proteína heterodimérica ou um anticorpo ativável e para tratar uma doença
BR112021018608A2 (pt) Anticorpos para claudina-6 e conjugados de fármaco
AR111361A1 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
BRPI0507433C1 (pt) anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit
BR112019008702A2 (pt) polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
BRPI0614040B8 (pt) anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
BR112017017029A2 (pt) polímeros de tiol-eno degradáveis e métodos para a sua fabricação
BR112017006591A2 (pt) polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
BR112012006492A2 (pt) proteína de fusão de anticorpo multivalente, e, ligação de albumina
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
BRPI0508862A (pt) métodos e construtos para expressar multìmeros de polipeptìdios em células eucarióticas utilizando junção alternativa
BR112013008407A2 (pt) antígenos de clostridium difficile
EA200970880A1 (ru) Стабильные композиции на основе антител
BR112012028326A2 (pt) anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
AR117728A1 (es) Moléculas superagonistas de unión al antígeno cd28 con diana tumoral
BRPI0515230A (pt) polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
PE20141561A1 (es) Anticuerpos anti-lrp5 y metodos de uso
EA201691779A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
BR112013020274A2 (pt) substitutos de proteínas pós-traducionalmente modificadas e usos dos mesmos
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.